BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 6, 2026
View BioWorld MedTech
Home » AI fertility company secures $6M for global expansion
To read the full story, subscribe or sign in.

AI fertility company secures $6M for global expansion

Jan. 6, 2022
By Catherine Longworth
Canadian company Future Fertility Inc. is hatching plans to expand the user base for its flagship egg prediction software product, Violet, for egg cryopreservation. The noninvasive image analysis tool uses artificial intelligence (AI) to evaluate the reproductive potential of mature eggs. Investors are backing the Toronto-based company with $6 million in series A funds, so it can expand internationally and develop additional assessment products.
Financings Medical technology Artificial intelligence Digital health Series A Canada

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • CINP 2026: Prenatal and adolescent stress shape brain vulnerability

    BioWorld Science
    Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
  • Ontrack Therapeutics divulges compounds for neurodegenerative diseases

    BioWorld Science
    Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
  • Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

    BioWorld Science
    Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
  • IPO puzzle pieces

    Neuracle eyes Shanghai IPO as global BCI funding surges

    BioWorld
    Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing